Loading clinical trials...
Loading clinical trials...
A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination with Bevacizumab and Hypofractionated Radiotherapy in Patients with Recurrent GBM
Conditions
Interventions
Bevacizumab
Biospecimen Collection
+5 more
Locations
3
United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
October 2, 2024
Primary Completion Date
November 30, 2026
Completion Date
November 30, 2030
Last Updated
November 19, 2024
NCT05789394
NCT06860594
NCT06344130
NCT05039281
NCT07209241
NCT06910306
Lead Sponsor
Academic and Community Cancer Research United
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions